Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2023 May 10:2023.05.10.540206.
doi: 10.1101/2023.05.10.540206.

Cardiomyocyte Targeting Peptide to Deliver Amiodarone

Affiliations

Cardiomyocyte Targeting Peptide to Deliver Amiodarone

Maliha Zahid et al. bioRxiv. .

Update in

  • Cardiomyocyte-Targeting Peptide to Deliver Amiodarone.
    Zahid M, Weber B, Yurko R, Islam K, Agrawal V, Lopuszynski J, Yagi H, Salama G. Zahid M, et al. Pharmaceutics. 2023 Aug 9;15(8):2107. doi: 10.3390/pharmaceutics15082107. Pharmaceutics. 2023. PMID: 37631321 Free PMC article.

Abstract

Background: Amiodarone is underutilized due to significant off-target toxicities. We hypothesized that targeted delivery to the heart would lead to lowering of dose by utilizing a cardiomyocyte targeting peptide (CTP), a cell penetrating peptide identified by our prior phage display work.

Methods: CTP was synthesized thiolated at the N-terminus, conjugated to amiodarone via Schiff base chemistry, HPLC purified and confirmed with MALDI/TOF. Stability of the conjugate was assessed using serial HPLCs. Guinea pigs (GP) were injected intraperitoneally daily with vehicle (7 days), amiodarone (7 days; 80mg/Kg), CTP-amiodarone (5 days;26.3mg/Kg), or CTP (5 days; 17.8mg/Kg), after which GPs were euthanized, hearts excised, perfused on a Langendorff apparatus with Tyrode's solution and blebbistatin (5μM) to minimize contractions. Voltage (RH237) and Ca 2+ -indicator dye (Rhod-2/AM) were injected, fluorescence from the epicardium split and focused on two cameras capturing at 570-595nm for cytosolic Ca 2+ and 610-750nm wavelengths for voltage. Subsequently, hearts were paced at 250ms with programmed stimulation to measure changes in conduction velocities (CV), action potential duration (APD) and Ca 2+ transient durations at 90% recovery (CaTD 90 ). mRNA was extracted from all hearts and RNA sequencing performed with results compared to control hearts.

Results: CTP-amiodarone remained stable for up to 21 days at 37°C. At ∼1/15 th of the dose of amiodarone, CTP-amiodarone decreased CV in hearts significantly compared to control GPs (0.92±0.05 vs. 1.00±0.03m/s, p=0.0007), equivalent to amiodarone alone (0.87±0.08ms, p=0.0003). Amiodarone increased APD (192±5ms vs. 175±8ms for vehicle, p=0.0025), while CTP-amiodarone decreased it significantly (157±16ms, p=0.0136) similar to CTP alone (155±13ms, p=0.0039). Both amiodarone and CTP-amiodarone significantly decreased calcium transients compared to controls. CTP-amiodarone and CTP decreased CaTD 90 to an extent greater than amiodarone alone (p<0.001). RNA-seq showed that CTP alone increased the expression of DHPR and SERCA2a, while decreasing expression of proinflammatory genes NF-kappa B, TNF-α, IL-1β, and IL-6.

Conclusions: Our data suggests that CTP can deliver amiodarone to cardiomyocytes at ∼1/15 th the total molar dose of amiodarone needed to produce comparable slowing of CVs. The ability of CTP to decrease AP durations and CaTD 90 may be related to its increase in expression of Ca-handling genes, and merits further study.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Schematic presentation of the CTP-amiodarone chemical structure. CTP is conjugated to amiodarone via a disulfide linker (circled in red).
Figure 2:
Figure 2:
HPLC Tracing of the CTP-amio conjugate immediately upon synthesis and purification (a), after 72 hours of incubation (b), and after 22 days of incubation (c) at 37°C.
Figure 3:
Figure 3:
CTP-Cy5.5 transduces rat cardiomyocytes in a cardiomyocyte-specific manner. Myofibroblasts are stained green with WGA-488 and show no co-localization with the CTP-Cy5.5 (red) that is taken up exclusively by cardiomyocytes. Nuclei stained blue (DAPI).
Figure 4:
Figure 4:
Comparison of heart rate (a), voltage conduction velocities (b), action potential duration (c), calcium conduction velocities (d) and CaT (e) between various treatment groups. All p-values are two-tailed, unpaired t-tests between each treatment group and controls.
Figure 5:
Figure 5:
Principal component analysis showing reasonable clustering within groups and separation between different treatment groups.
Figure 6:
Figure 6:
Differentially expressed genes in CTP treated guinea pig hearts compared with control hearts. β2-adrenergic receptor is significantly down-regulated, whereas α-adrenergic, receptor and calcium handling genes (DHPR and SERCA2a) are significantly upregulated (all circled in black).
Figure 7:
Figure 7:
Differentially expressed genes (DEGs) in CTP treated guinea pig hearts compared with control hearts. Pro-inflammatory genes in the NF-κB pathway (IκBα), as well as TNF-α, IL-1β, and COX2 are significantly down-regulated (all circled in black).

Similar articles

References

    1. Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Rev Cardiol. 2014;11:639–654. doi: 10.1038/nrcardio.2014.118 - DOI - PubMed
    1. Turakhia MP, Shafrin J, Bognar K, Trocio J, Abdulsattar Y, Wiederkehr D, Goldman DP. Estimated prevalence of undiagnosed atrial fibrillation in the United States. PLoS One. 2018;13:e0195088. doi: 10.1371/journal.pone.0195088 - DOI - PMC - PubMed
    1. Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, Newton-Cheh C, Lubitz SA, Magnani JW, Ellinor PT, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015;386:154–162. doi: 10.1016/S0140-6736(14)61774-8 - DOI - PMC - PubMed
    1. Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, Noseworthy PA, Rosenberg YD, Jeffries N, Mitchell LB, et al. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA. 2019;321:1261–1274. doi: 10.1001/jama.2019.0693 - DOI - PMC - PubMed
    1. Willems S, Borof K, Brandes A, Breithardt G, Camm AJ, Crijns H, Eckardt L, Gessler N, Goette A, Haegeli LM, et al. Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. Eur Heart J. 2022;43:1219–1230. doi: 10.1093/eurheartj/ehab593 - DOI - PMC - PubMed

Publication types